Liquid Losartan Available Now
Arbli™ is FDA-approved and available in the U.S. through traditional full-line wholesalers.
Why Arbli™
Arbli is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older to lower blood pressure.1
FDA-approved Arbli is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
Compare Arbli versus compounded losartan below.
Arbli™ vs. Compounded Losartan
Developed by scientific experts, Arbli is an FDA-approved liquid losartan specifically designed for hypertensive patients struggling with dysphagia, or difficulty swallowing. Since 1995, when losartan was introduced as the brand COZAAR® (losartan potassium), angiotensin II receptor blockers (or ARBs) have been a trusted medicine to help lower blood pressure.
| Arbli oral suspension1 | Compounded losartan suspension2 |
|---|---|
 Higher concentration: 10 mg/mL |  Lower concentration: 2.5 mg/mL |
| FDA-approved formulation that's ready to use |  Not FDA-approved as a ready-to-use formulation3 |
| No refrigeration needed - store at room temperature1 |  Must be kept refrigerated2 |
| Longer shelf life: Opened, 60 days at room temperature1 | Once prepared, up to 4 weeks, requires refrigeration |
Key Benefits of Arbli™ for Patients
The Benefits of Arbli™
For some people, swallowing pills can be an obstacle to staying on their chronic hypertension therapy.
Arbli is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction.
These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan.
- Easy to swallow, less risk of choking
- Pleasant, soothing peppermint flavor
- One 5 mL dose is the same amount of losartan as a COZAAR® 50 mg tablet
- Can help reduce interruption in therapy due to swallowing difficulties
- Flexible dosing in 10 mg/mL can cover the 25 mg, 50 mg, and 100 mg tablet therapies with less volume than compounded Rxs
Actor portrayal, not actual patient
Arbli™ Product Overview
For patients who need a liquid losartan formulation.
- 10 mg/mL
- Room temperature for 24 months, unopened
- No refrigeration required
- Shake-and-dispense
- Peppermint flavor
- Eliminates need for compounding
- FDA-approved formulation delivers consistent potency, efficacy, and safety
- Can reduce potential risks associated with crushing or compounding tablets
- Flexible, easy-to-tailor dosing compared to compounding, which requires additional steps for preparation
References
- ARBLITM [prescribing information]. Commack, NY: Scienture, LLC. 2025
- COZAAR® label. Accessed on dailymed.nlm.nih.gov. COZAAR® label provides suspension is 2.5 mg/mL in 200 mL solution.
- FDA/CDER. Guidance for Industry: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act. January 2018.
COZAAR® is a registered trademark of N.V. Organon.
